Cutaneous Crohns

Article Author:
Courtney Bernett
Article Editor:
Karthik Krishnamurthy
10/27/2018 12:32:04 PM
PubMed Link:
Cutaneous Crohns


Crohn’s disease, a well-known subtype of inflammatory bowel disease, is an inflammatory condition of the gastrointestinal tract with numerous possible extra-intestinal manifestations. Approximately 40% of all patients affected by Crohn’s disease experience at least one extra-intestinal manifestations of the disease, with the skin being the most common site of extra-intestinal involvement. Other common locations of extra-intestinal involvement include the eyes, joints, and hepatobiliary system. Interestingly, an extra-intestinal manifestation may precede the formal diagnosis of Crohn’s disease in about 25% patients.


Although the underlying etiology of Crohn’s disease remains fundamentally unknown, the largely accepted theory involves exposure to “triggers” (i.e., microbial, environmental, immunological) in a genetically susceptible person. The chronic inflammatory component of Crohn disease is likely driven by altered activation of both Th1 and Th17 immune pathways with elevated levels of interleukins 23 and 17. Polymorphisms of the NOD2/CARD15 genes may further affect the innate immune response. Interestingly, patients with an altered TRAF3IP2 gene may be predisposed to developing cutaneous involvement of their Crohn's disease. Other studies have shown altered intestinal flora (shifts in composition or decreased diversity) in patients with Crohn's disease. Precise etiology and pathogenesis are also limited to the cutaneous manifestations of Crohn’s disease, but assistance in understanding and categorizing these skin findings come from the following three well-accepted categories:

Specific lesions: lesions have histopathological findings consistent with Crohn’s disease on biopsy. This may be further subcategorized to the following:

  • Cutaneous lesion occurring due to a direct extension of bowel disease to the skin
  • Metastatic Crohn’s disease: skin lesions with characteristic findings of Crohn’s disease on biopsy, but at sites distant from the gastrointestinal (GI) tract (noncontiguous).

Reactive lesions: inflammatory lesions that do not share the same histopathological findings.

Associated lesions: likely develop due to shared HLA-gene types or secondary to chronic inflammatory response.

A fourth category is suggested by some authors and encompasses the cutaneous manifestations that may be induced by the treatment of Crohn’s disease, particularly with anti-TNF therapy.


The onset of Crohn’s disease may occur at any age from childhood up to the seventh decade of life, with a majority of the cases diagnosed in young adults between 15 to 30 years of age. Interestingly, approximately 25$ to 35% of all cases of Crohn’s disease are diagnosed in patients younger than 18 years of age. Both the incidence and prevalence of Crohn’s disease have been increasing over the past few decades, particularly in well-developed countries. In the United States, approximately 246 people per 100,000 population are affected by Crohn’s disease and statistically, between 20% to 33% of those patients will experience a dermatological manifestation of their Crohn’s disease.

History and Physical

The clinical presentation of Crohn's disease is immensely diverse and may include any or a combination of any of the following: abdominal pain, anorexia, weight loss, diarrhea, hematochezia, melena, malnutrition, fatigue, fevers, and bowel obstruction secondary to stricture formation. The cutaneous manifestations of Crohn's disease may also aid in establishing the diagnosis of Crohn's disease as their presence may antedate the formal inflammatory bowel disease diagnosis. Although Crohn's disease is well known for its ability to affect any part of the GI tract, from the oral mucosa to the anus, most of the disease is non-contiguous and restricted to the ileum and colon.

Each of the respective categories of the cutaneous manifestations of Crohn disease and their manifestations will be discussed below:

Specific lesions:  lesions with histopathological findings consistent with Crohn’s disease on biopsy.

a) Cutaneous lesions which occur due to a direct extension of bowel disease to the skin and are typically seen in the perianal and orofacial areas. Clinically, on the exam, the lesions may be ulcers, fistulae, fissures, or even abscesses and on biopsy, non-caseating granulomatous inflammation can be seen. Many do not actually consider these to truly be an "extra-intestinal" manifestation of Crohn's disease.

  • Perianal fissures/fistulae: Very common finding in up to 33% of patients with Crohn's disease and is generally more indicative of colonic involvement. Some authors do not consider this to be a true extra-intestinal manifestation of Crohn's disease due to its close location to the anus. Patients may develop acrochordons or "sentinel tags" in the perianal area as well.

b) Metastatic Crohn’s disease: Rare manifestation of cutaneous Crohn's disease characterized by skin lesions with findings of Crohn’s disease on biopsy, but at sites distant and noncontiguous with the GI tract (must be separated from the GI tract by normal tissue).

  • Generally, the lesions are plaques and/or nodules with a red to a purple hue that may even have an ulcerative component. They may also have an appearance similar to those mentioned above in the direct extension of intestinal disease category. The most common sites of involvement include the intertriginous area, extremities, face, and genitalia.              

Reactive lesions: Inflammatory lesions that do not share the same histopathological findings, but are believed to share a similar pathogenesis with Crohn's disease, perhaps due to impaired function of neutrophils or altered cellular immunity.

  • Pyoderma gangrenosum (PG): Although pyoderma gangrenosum is more commonly associated with ulcerative colitis, it may still be seen in patients with Crohn's disease as well. Presence of a pyoderma gangrenosum should prompt physicians to consider a diagnosis of IBD in these patients as well, as 20% to 50% of patients with PG have coexistent IBD. These lesions classically start as tender papulopustules with a surrounding erythematous to the violaceous rim. The area then starts to undergo necrosis, leading to an ulcerated area. Fully developed lesions are best described as an ulcer with a sterile, purulent base with an irregular, undermined, gun-metal border. The most common location in adults is in the lower extremities, but in children, they are more likely to occur on the head or in the anogenital region. Lesions of PG may be initiated of aggravated by seemingly minor trauma and may also exhibit pathergy. Lesions tend to heal with significant scarring. Diagnosis is generally made clinically as histopathological findings are non-specific.
  • Sweet syndrome: Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a relatively uncommon disease entity. Although it does have an association with IBD, it is more commonly seen in association with upper respiratory infections due to Streptococcus, gastrointestinal Yersiniosis infections, hematological malignancies (AML) and solid tumors of the breast, colon, and GU tract. Female patients are more commonly affected than males and children are rarely affected. The lesions typically start as tender, erythematous, edematous papules and plaques that favor the head, neck, and upper extremities. As with pyoderma gangrenosum, the lesions of Sweet's syndrome may also exhibit pathergy. Systemic findings including fever, leukocytosis, arthralgias, myalgias, and ocular involvement (conjunctivitis, episcleritis) are commonly seen in Sweet's syndrome. Diagnosis is generally made clinically, and biopsy generally shows a nodular and perivascular neutrophilic infiltrate.

Associated lesions: likely arise due to shared HLA-gene types or secondary to a chronic inflammatory response. Interestingly, the presence and severity of the cutaneous manifestations listed below generally parallel intestinal disease activity.

  • Erythema nodosum (EN): Erythema nodosum is a fairly common cutaneous finding associated with Crohn's disease with reports ranging from 6% to 15% of patients affected. The presence of EN is not exclusive to Crohn's disease and has many other disease associations including: malignancies, pregnancy, use of oral contraceptive medications, autoimmune disease, and infections, such as streptococcus and tuberculosis. The typical clinical presentation includes a female patient wth tender, erythematous nodules overlying the anterior tibia. A biopsy is seldom needed to make the diagnosis, but early lesions may reveal a septal panniculitis if examined histologically. A biopsy may also prove beneficial to help rule out metastatic Crohn's disease.
  • Oral lesions: Oral lesions are also a common cutaneous finding associated with Crohn's disease with approximately 10% of patients experiencing either aphthous ulcerations, pyostomatitis vegetans, or periodontitis. The presentation of each of the previously mentioned manifestations differ, but all three are similar in the fact that they cause oral pain and discomfort. Patient with aphthous stomatitis develops painful, shallow ulcerations, with a fibrinous base and surrounding erythema on the buccal or labial mucosa. Pyostomatitis vegetans also affects the labial and buccal mucosa with friable mucosa scattered with erosions and ulcerations. Peridontitis is not specific for Crohn's disease or ulcerative colitis, but the more severe disease has been noted in patients with inflammatory bowel disease. The biopsy is rarely required to diagnose any of those above.

Treatment-induced: A novel category of cutaneous findings that are most commonly associated with the treatment of Crohn's disease with anti-TNF biologics. The cutaneous manifestations of anti-TNF treatment do not correlate with disease activity status.

  • Anti-TNF-associated skin lesions: Anti-TNF-associated skin lesions were previously regarded as a rare occurrence, but now are becoming more prevalent with the popular use of anti-TNFs in numerous different disease entities including rheumatoid arthritis and psoriasis. It has been estimated that 5% to 10% of patients with IBD treated with an anti-TNF will develop an anti-TNF induced skin lesion. Eczematous and psoriasiform skin changes are the most common findings.

The relative absence or presence of the above cutaneous extra-intestinal manifestations may be helpful in monitoring the disease course of Crohn's disease, particularly in patients displaying oral aphthous ulcerations or erythema nodosum, as they may clue to the physician to evaluate for active intestinal disease, even in relatively asymptomatic patients.


Diagnosis of Crohn's disease is generally made via endoscopic evaluation of intestinal mucosa along with biopsy showing granulomatous changes and crypt irregularities. Additional laboratory evaluation, including blood tests, may also be utilized.

Treatment / Management

Treatment for the plethora of cutaneous manifestations of Crohn's disease are extensively varied. Each of manifestations that were discussed above will be briefly discussed below.

Specific lesions: lesions with histopathological findings consistent with Crohn’s disease on biopsy

  • Cutaneous lesion occurs due to a direct extension of bowel disease to the skin. In general, surgical intervention is required.
  • Metastatic Crohn’s disease: Treatment of metastatic Crohn's disease often proves to be significantly difficult. Few therapeutic options are available with very limited information regarding the efficacy of the therapies. Case reports have suggested the use of immunomodulators, such as anti-TNF biologics, or topical or systemic corticosteroids.

Reactive lesions: inflammatory lesions that do not share the same histopathological findings, but are believed to share a similar pathogenesis with Crohn's disease.

  • Pyoderma gangrenosum (PG): Goals of treatment should include reduction of the inflammatory process to promote healing, pain reduction, and control of underlying IBD (particularly if PG lesions seem to parallel Crohn's disease course). Patients should be educated about daily wound care, and referral to a wound care center may be helpful. Generally, the first line systemic therapy for PG is systemic corticosteroids (0.5 to 2 mg/kg/day), and concurrent use of local corticosteroid therapy may be implemented as well. Should the PG prove refractory to corticosteroids, oral or, intravenous (IV) cyclosporine or anti-TNF agents should be considered. Surgery and debridement should be avoided as a treatment for PG due to potential pathergy. Unfortunately, remission may be short-lived because as many as 25% of patients will experience recurrent disease.
  • Sweet's syndrome: Disease is self-limited, and most lesions completely resolve without scarring in 1 to 3 months, but recurrence occurs in about one-third of patients. Oral corticosteroids such as prednisone (0.5 to 1 mg/kg/day) may be used for 4 to 6 weeks and lesions generally improve or resolve quickly. For localized disease, topical or intralesional steroids may be more appropriate.

Associated lesions: likely arise due to shared HLA-gene types or secondary to a chronic inflammatory response.

  • Erythema nodosum: Disease is self-limited and resolves without scarring. As the presence of erythema nodosum tends to parallel the activity of intestinal disease, treatment directed at achieving better control of the patient's Crohn's disease is recommended. Leg elevation, compression hose, and pain control should be implemented as well. In severe or refractory cases, systemic corticosteroids (0.5 to 1 mg/kg/day) should be initiated. Anti-TNF agents may be required if there is the absence of an adequate response to prednisone.
  • Oral lesions: Oral lesions such as aphthous ulcerations, pyostomatitis vegetans, and periodontitis disease activity are positively correlated to underlying intestinal disease activity. First line management should be aimed at achieving better control of the Crohn's disease with supportive care with antiseptic and analgesic mouthwashes plus or minus local corticosteroids.

Treatment-induced: A novel category of cutaneous findings that are most commonly associated with the treatment of Crohn's disease with anti-TNF biologics.

  • Anti-TNF-associated skin lesions: As previously stated, withdraw of the anti-TNF should result in resolution of the lesions; however, this is often not necessary as the eczematous or psoriasiform skin changes may be managed with various topical treatments including topical corticosteroids, emollients, vitamin D analogs, and phototherapy.


Cutaneous Manifestations of Crohn Disease., Hagen JW,Swoger JM,Grandinetti LM,, Dermatologic clinics, 2015 Jul     [PubMed PMID: 26143422]
Cutaneous manifestations of gastrointestinal disease: part II., Thrash B,Patel M,Shah KR,Boland CR,Menter A,, Journal of the American Academy of Dermatology, 2013 Feb     [PubMed PMID: 23317981]
Pathophysiology of inflammatory bowel disease: an overview., Thoreson R,Cullen JJ,, The Surgical clinics of North America, 2007 Jun     [PubMed PMID: 17560413]
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease., Brand S,, Gut, 2009 Aug     [PubMed PMID: 19592695]
Skin Manifestations of Inflammatory Bowel Disease., Greuter T,Navarini A,Vavricka SR,, Clinical reviews in allergy & immunology, 2017 Dec     [PubMed PMID: 28643285]
Epidemiology of inflammatory bowel disease., Loftus EV Jr,Sandborn WJ,, Gastroenterology clinics of North America, 2002 Mar     [PubMed PMID: 12122726]
Inflammatory bowel disease., Kaser A,Zeissig S,Blumberg RS,, Annual review of immunology, 2010     [PubMed PMID: 20192811]
The microbiome in inflammatory bowel disease: current status and the future ahead., Kostic AD,Xavier RJ,Gevers D,, Gastroenterology, 2014 May     [PubMed PMID: 24560869]
Disease-specific alterations in the enteric virome in inflammatory bowel disease., Norman JM,Handley SA,Baldridge MT,Droit L,Liu CY,Keller BC,Kambal A,Monaco CL,Zhao G,Fleshner P,Stappenbeck TS,McGovern DP,Keshavarzian A,Mutlu EA,Sauk J,Gevers D,Xavier RJ,Wang D,Parkes M,Virgin HW,, Cell, 2015 Jan 29     [PubMed PMID: 25619688]
Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort., Vavricka SR,Brun L,Ballabeni P,Pittet V,Prinz Vavricka BM,Zeitz J,Rogler G,Schoepfer AM,, The American journal of gastroenterology, 2011 Jan     [PubMed PMID: 20808297]
Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity., Veloso FT,Ferreira JT,Barros L,Almeida S,, Inflammatory bowel diseases, 2001 Nov     [PubMed PMID: 11720320]
Mucocutaneous manifestations in inflammatory bowel disease., Yüksel I,Başar O,Ataseven H,Ertuğrul I,Arhan M,Ibiş M,Dağli U,Demirel BT,Ulker A,Seçilmiş S,Saşmaz N,, Inflammatory bowel diseases, 2009 Apr     [PubMed PMID: 19023896]
Extraintestinal manifestations and complications in inflammatory bowel diseases., Rothfuss KS,Stange EF,Herrlinger KR,, World journal of gastroenterology, 2006 Aug 14     [PubMed PMID: 16937463]
Metastatic Crohn's Disease: An Approach to an Uncommon but Important Cutaneous Disorder., Aberumand B,Howard J,Howard J,, BioMed research international, 2017     [PubMed PMID: 28127561]
Urogenital Manifestations of Metastatic Crohn's Disease in Children: Case Series and Review of the Literature., Rani U,Russell A,Tanaka S,Correa H,Nicholson MR,, Urology, 2016 Jun     [PubMed PMID: 26921647]
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease., Ogura Y,Bonen DK,Inohara N,Nicolae DL,Chen FF,Ramos R,Britton H,Moran T,Karaliuskas R,Duerr RH,Achkar JP,Brant SR,Bayless TM,Kirschner BS,Hanauer SB,Nuñez G,Cho JH,, Nature, 2001 May 31     [PubMed PMID: 11385577]
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease., Ciccacci C,Biancone L,Di Fusco D,Ranieri M,Condino G,Giardina E,Onali S,Lepre T,Pallone F,Novelli G,Borgiani P,, Journal of Crohn's & colitis, 2013 Feb     [PubMed PMID: 22445837]